Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $35.00 price target on the biopharmaceutical company's stock. HC Wainwright's target price suggests a potential upside of 58.37% from the stock's current price.
CPRX has been the subject of several other research reports. Bank of America reissued a "buy" rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. StockNews.com downgraded Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, January 11th. Robert W. Baird began coverage on Catalyst Pharmaceuticals in a research report on Tuesday, February 4th. They set an "outperform" rating and a $28.00 price objective on the stock. Finally, Truist Financial boosted their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals has an average rating of "Buy" and a consensus target price of $32.50.
Get Our Latest Stock Report on Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Price Performance
Catalyst Pharmaceuticals stock traded down $0.22 during mid-day trading on Friday, reaching $22.10. The stock had a trading volume of 988,851 shares, compared to its average volume of 1,278,072. Catalyst Pharmaceuticals has a one year low of $14.47 and a one year high of $24.64. The company has a 50-day moving average price of $22.26 and a two-hundred day moving average price of $21.47. The company has a market capitalization of $2.68 billion, a price-to-earnings ratio of 18.73, a PEG ratio of 3.31 and a beta of 0.80.
Insiders Place Their Bets
In other news, insider Steve Miller sold 50,000 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now owns 686,996 shares of the company's stock, valued at $15,065,822.28. The trade was a 6.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 11.00% of the company's stock.
Hedge Funds Weigh In On Catalyst Pharmaceuticals
A number of institutional investors have recently bought and sold shares of CPRX. Creative Planning raised its stake in shares of Catalyst Pharmaceuticals by 26.9% in the third quarter. Creative Planning now owns 12,724 shares of the biopharmaceutical company's stock worth $253,000 after buying an additional 2,699 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Catalyst Pharmaceuticals by 11.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 20,017 shares of the biopharmaceutical company's stock valued at $398,000 after purchasing an additional 1,989 shares in the last quarter. DekaBank Deutsche Girozentrale increased its stake in shares of Catalyst Pharmaceuticals by 48.6% in the third quarter. DekaBank Deutsche Girozentrale now owns 183,376 shares of the biopharmaceutical company's stock worth $3,532,000 after purchasing an additional 60,000 shares in the last quarter. Summit Global Investments lifted its stake in shares of Catalyst Pharmaceuticals by 2.6% during the 3rd quarter. Summit Global Investments now owns 77,292 shares of the biopharmaceutical company's stock valued at $1,537,000 after buying an additional 1,923 shares in the last quarter. Finally, CWA Asset Management Group LLC purchased a new stake in Catalyst Pharmaceuticals in the 3rd quarter worth $534,000. 79.22% of the stock is owned by institutional investors.
Catalyst Pharmaceuticals Company Profile
(
Get Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Further Reading
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
